



Par Pharmaceutical  
6 Ram Ridge Road  
Chestnut Ridge, NY 10977  
Tel: 845-573-5500  
Fax: 845-426-0410  
www.parpharm.com

June 5, 2019

[AGO.highcostprescriptiondrugs@vermont.gov](mailto:AGO.highcostprescriptiondrugs@vermont.gov)

Notice of a New Prescription Drug Pursuant to 18 V.S.A. § 4637(b)

Dear Office of the Vermont Attorney General,

Par Pharmaceutical, Inc. (“Par”) is issuing this notice pursuant to 18 V.S.A. § 4637(b), which asks prescription drug manufacturers to provide the Office of the Attorney General (the “Office”) written notice within three calendar days of releasing a drug in the commercial market whose wholesale acquisition cost (“WAC”) exceeds the threshold set for a specialty drug under the Medicare Part D Program.

On June 3, 2019, Par informed potential customers the following drug products are available for order:

<b>NDC #</b>	<b>Product Description</b>
49884-0058-02	Bosentan Tablets 62.5mg 60s
49884-0059-02	Bosentan Tablets 125mg 60s

The WAC for the drug product(s) identified above exceeds the threshold set for a specialty drug under the Medicare Part D Program. Please note that the WAC-related information provided in this notice may be subject to change.

18 V.S.A. § 4637 does not currently define “release of the drug in the commercial market.” Further, Par is not aware of any guidance issued by the Office or any Vermont regulation that defines “release of the drug in the commercial market” for the purpose of 18 V.S.A. § 4637.

Par interprets “release of the drug in the commercial market” to mean when Par informs potential customers that a drug is available for order.

In the event Vermont S. 92 and the laws it implements, including 18 V.S.A. § 4637, are found invalid, Par reserves all of its legal rights. In issuing this notice in an attempt to comply with 18 V.S.A. § 4637, Par does not waive any legal claims or legal rights related to potential constitutional defects with Vermont S. 92.

Sincerely,

Michael Altamuro, SVP, Commercial Operations & Marketing